➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Boehringer Ingelheim
AstraZeneca
Express Scripts
Merck

Last Updated: January 20, 2021

DrugPatentWatch Database Preview

Litigation Details for MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC. (D.N.J. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for MITSUBISHI TANABE PHARMA CORPORATION v. SANDOZ INC. (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
2017-07-20 1 infringement of United States Patent No. 7,943,788 (“the ’788 patent”), United States Patent No. 8,222,219 (“the…the ’219 patent”), and United States Patent No. 8,785,403 (“the ’403 patent”) (collectively, “the patents-in-suit….S.C. § 355(b)(l), the ’788 patent, the ’219 patent, and the ’403 patent are listed in the United States… THE PATENTS-IN-SUIT 19. On May 17, 2011, the ’788 patent, titled “Glucopyranoside…the ’788 patent. 21. JNV is an exclusive sublicensee of the ’788 patent. External link to document
2020-02-09 128 Stipulation and Order it is the owner of United States Patent No. 7,943,788 (“the ’788 patent”). WHEREAS, Sandoz has filed Abbreviated…District Court for the District of New Jersey for patent infringement based on Sandoz’s filing of ANDA … 20 July 2017 3:17-cv-05319 835 Patent - Abbreviated New Drug Application(ANDA) None External link to document
2020-05-28 166 Trial Brief disclosed in the ’117 patent126 patent U.S. Patent No. 6,414,126 …Example 10 Example 10 of U.S. Patent No. 6,414,126 FDA United States …788 patent, claim 22 of the ’219 patent, and claim 26 of the ’403 patent BMS…Seiyaku Co., Ltd. patents-in-suit U.S. Patent No. 7,943,788 (“the ’788 patent”), … U.S. Patent No. 8,222,219 (“the ’219 patent”), and U.S. Patent No. 8,785,403 External link to document
2020-06-15 173 Opinion infringement of U.S. Patent Nos. 7,943,788 (“the ’788 patent), 8,222,219 (“the ’219 patent), and 8,785,403… (“the ’403 patent”) (collectively, “the patents-in-suit”). Compl. at ¶ 10. The patents-in-suit are… B. Local Patent Rules Pursuant to the Local Patent Rules for the District of…Local Patent Rules. Zydus contends that the “priority date” disclosure required by Local Patent Rule….D. Cal. July 17, 2015) (“Patent L.R. 3-1(f) particularly requires a patent holder to assert a specific External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
Medtronic
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.